Drugs that contain Midostaurin

1. List of Rydapt drug patents

RYDAPT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2022

(4 months ago)

US7973031 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2028

(5 years from now)

US8575146 NOVARTIS Pharmaceutical uses of staurosporine derivatives
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 28, 2024

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolid...

Dosage: CAPSULE;ORAL

How can I launch a generic of RYDAPT before it's patent expiration?
More Information on Dosage

RYDAPT family patents

10

United States

4

China

4

European Union

3

Australia

3

Japan

3

Canada

2

Denmark

2

Austria

2

Mexico

2

Hong Kong

2

Slovenia

2

Hungary

2

Germany

2

Brazil

2

Portugal

2

Spain

2

Korea, Republic of

2

Poland

2

Taiwan, Province of China

1

Israel

1

South Africa

1

Russia

1

Norway

1

Cyprus

1

Netherlands

1

Luxembourg

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic